Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants

Vaccine
M KnufH J Schmitt

Abstract

To evaluate immunogenicity, reactogenicity, and safety of a hexavalent combination vaccine diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b (DTPa-HBV-IPV/Hib) when coadministered with a 7-valent pneumococcal conjugate vaccine (PCV7). Infants received either a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-H. influenzae type b vaccine concomitantly with PCV7 or DTPa-HBV-IPV/Hib alone infants were vaccinated at 2, 3 and 4 months (primary immunization) and 12-15 months of age (booster dose). Local and systemic reactions and adverse events were monitored following each dose and compared between groups. Blood was obtained prior to dose 1, one month after dose 3, immediately prior to and 1 month following the booster dose to measure antibody responses to each of the antigens. Two hundred and fifty-three subjects (PCV7, 127; Control, 126) were enrolled. Antibody responses were compared in 226 subjects for the primary immunization and 212 for the booster dose (per-protocol (PP) population). Although there were some differences in geometric mean concentrations (GMCs) to the DTPa-HBV-IPV/Hib antigens after the primary series, GMCs for all antig...Continue Reading

Citations

Jun 12, 2008·Bulletin of the World Health Organization·Frank DestefanoHanna Nohynek
Sep 8, 2010·BMC Infectious Diseases·Sun-Young KimSue J Goldie
May 17, 2011·Journal of Global Infectious Diseases·David Ag SkibinskiDerek T O'Hagan
Dec 18, 2013·The Pediatric Infectious Disease Journal·Maria Deloria KnollKatherine L O'Brien
Aug 28, 2010·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Sohita Dhillon
Oct 30, 2012·The Pediatric Infectious Disease Journal·Kristina A BryantDaniel A Scott
Aug 10, 2012·Paediatric Drugs·Katherine A Lyseng-Williamson, Sohita Dhillon
Oct 7, 2009·Expert Review of Vaccines·Markus Rose, Stefan Zielen
Jun 3, 2009·Expert Review of Vaccines·Fred ZeppJeanne-Marie Jacquet
Nov 3, 2011·Expert Review of Vaccines·Ray BorrowJan Poolman
Aug 3, 2011·Expert Review of Vaccines·Marta C Nunes, Shabir A Madhi
Jun 15, 2007·Journal of Comparative Pathology·C-A Siegrist
Apr 22, 2015·Human Vaccines & Immunotherapeutics·Malabi M Venkatesan, Lillian L Van de Verg
Jan 28, 2014·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·S EspositoN Principi
Aug 7, 2012·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·L F Pittet, K M Posfay-Barbe
Nov 7, 2019·The Cochrane Database of Systematic Reviews·Karla Soares-WeiserNigel Cunliffe
Mar 26, 2011·Expert Review of Vaccines·Tirdad T ZangenehJaffar A Al-Tawfiq
Mar 10, 2020·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Young June ChoeEun Hwa Choi
May 19, 2010·Pediatrics·Alfredo PisacaneUgo Vairo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Meningitis (ASM)

Bacterial meningitis continues to be an important cause of mortality and morbidity throughout the world. Here is the latest research.

Bacterial Meningitis

Bacterial meningitis continues to be an important cause of mortality and morbidity throughout the world. Here is the latest research.